Antitumor Activity of Microbial Products and Tumor Necrosis Factor

2015 ◽  
pp. 7-19 ◽  
Author(s):  
Lloyd J. Old
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Tumor Necrosis ◽  
Microbial Products ◽  
Necrosis Factor

scholarly journals Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α

2006 ◽  
Vol 12 (1) ◽  
pp. 175-182 ◽  
Author(s):  
Angelina Sacchi ◽  
Anna Gasparri ◽  
Corrado Gallo-Stampino ◽  
Salvatore Toma ◽  
Flavio Curnis ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Tumor Vasculature ◽  
Factor Α ◽  
Necrosis Factor ◽  
Synergistic Antitumor Activity

Antitumor Activity of a Novel Chimera Tumor Necrosis Factor (TNF-STH) Constructed by Connecting rTNF-S with Thymosin β4 Against Murine Syngeneic Tumors

1991 ◽  
Vol 10 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Katsuo Noguchi ◽  
Hiroyuki Inagawa ◽  
Yoshiaki Tsuji ◽  
Akinobu Morikawa ◽  
Den-Ichi Mizuno ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Tumor Necrosis ◽  
Thymosin Β4 ◽  
Necrosis Factor ◽  
Syngeneic Tumors

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

2010 ◽  
Vol 28 (17) ◽  
pp. 2839-2846 ◽  
Author(s):  
Roy S. Herbst ◽  
S. Gail Eckhardt ◽  
Razelle Kurzrock ◽  
Scot Ebbinghaus ◽  
Peter J. O'Dwyer ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Liver Function ◽  
Phase I ◽  
Liver Metastases ◽  
Advanced Cancer ◽  
Dose Escalation ◽  
Tumor Necrosis ◽  
Dose Escalation Study ◽  
Necrosis Factor

Purpose Apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (Apo2L/TRAIL)—a member of the tumor necrosis factor cytokine family—induces apoptosis by activating the extrinsic pathway through the proapoptotic death receptors DR4 and DR5. Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy. To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer. Patients and Methods This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2). Doses were given daily for 5 days, with cycles repeating every 3 weeks. Assessments included adverse events (AEs), laboratory tests, pharmacokinetics, and imaging to evaluate antitumor activity. Results Seventy-one patients received a mean of 18.3 doses; seven patients completed all eight treatment cycles. The AE profile of rhApo2L/TRAIL was similar in cohorts 1 and 2. The most common AEs were fatigue (38%), nausea (28%), vomiting (23%), fever (23%), anemia (18%), and constipation (18%). Liver enzyme elevations were concurrent with progressive metastatic liver disease. Two patients with sarcoma (synovial and undifferentiated) experienced serious AEs associated with rapid tumor necrosis. Two patients with chondrosarcoma experienced durable partial responses to rhApo2L/TRAIL. Conclusion At the tested schedule and dose range, rhApo2L/TRAIL was safe and well tolerated. Dose escalation achieved peak rhApo2L/TRAIL serum concentrations equivalent to those associated with preclinical antitumor efficacy.

scholarly journals Improved Antitumor Activity and Tumor Targeting of NH2-Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand

2010 ◽  
Vol 9 (6) ◽  
pp. 1719-1729 ◽  
Author(s):  
Su Young Chae ◽  
Tae Hyung Kim ◽  
Kyeongsoon Park ◽  
Cheng-Hao Jin ◽  
Sohee Son ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Tumor Targeting ◽  
Tumor Necrosis ◽  
Necrosis Factor

Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins

APOPTOSIS ◽  
2013 ◽  
Vol 18 (5) ◽  
pp. 618-626 ◽  
Author(s):  
Lan Yang ◽  
Qiong Wang ◽  
Daoxia Li ◽  
Yuqiong Zhou ◽  
Xuelian Zheng ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Antitumor Activity ◽  
Tumor Necrosis ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document